Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment
Theranostics · 2023 · 13 (9) · 2734-2756
DOI: 10.7150/thno.82005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Theranostics, 2023. Verfasst von Nerea Iturrioz-Rodríguez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Oncology group, Biodonostia Health Research Institute, San Sebastian, Spain. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 84-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Glioblastoma is the most common and lethal brain tumor in adults. The incorporation of temozolomide (TMZ) into the standard treatment has increased the overall survival rate of glioblastoma patients. Since then, significant advances have been made in understanding the benefits and limitations of TMZ. Among the latter, the unspecific toxicity of TMZ, poor solubility, and hydrolyzation are intrinsic characteristics, whereas the presence of the blood-brain barrier and some tumor properties, such as molecular and cellular heterogeneity and therapy resistance, have limited the therapeutic effects of TMZ in treating glioblastoma. Several reports have revealed that different strategies for TMZ encapsulation in nanocarriers overcome those limitations and have shown that they increase TMZ stability, half-life, biodistribution, and efficacy, offering the promise for future nanomedicine therapies in handling glioblastoma. In this review, we analyze the different nanomaterials used for the encapsulation of TMZ to improve its stability, blood half-life and efficacy, paying special attention to polymer- and lipid-based nanosystems. To improve TMZ drug resistance, present in up to 50% of patients, we detail TMZ combined therapeutic with i) other chemotherapies, ii) inhibitors, iii) nucleic acids, iv) photosensitizers and other nanomaterials for photodynamic therapy, photothermal therapy, and magnetic hyperthermia, v) immunotherapy, and vi) other less explored molecules. Moreover, we describe targeting strategies, such as passive targeting, active targeting to BBB endothelial cells, glioma cells, and glioma cancer stem cells, and local delivery, where TMZ has demonstrated an improved outcome. To finish our study, we include possible future research directions that could help decrease the time needed to move from bench to bedside.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular Oncology group, Biodonostia Health Research Institute, San Sebastian, Spain.
- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
- Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento (CIBERfes), Carlos III Institute, Madrid, Spain.
Zitieren
APA
Iturrioz-Rodríguez, N., Sampron, N., & Matheu, A. (2023). Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment. Theranostics, 13(9), 2734-2756. https://doi.org/10.7150/thno.82005
Vancouver
Iturrioz-Rodríguez N, Sampron N, Matheu A. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment. Theranostics. 2023;13(9):2734-2756. doi:10.7150/thno.82005
BibTeX
@article{IturriozRodrguez2023,
author = {Iturrioz-Rodríguez, Nerea and Sampron, Nicolas and Matheu, Ander},
title = {Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment},
journal = {Theranostics},
year = {2023},
volume = {13},
number = {9},
pages = {2734--2756},
doi = {10.7150/thno.82005}
}
EUVIMED